Q-omics provides the consensus-scored C8orf82 profile across patient tissues and cancer cell-line models. C8orf82 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C8orf82 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, C8orf82 RNA expression shows 17,210 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRP, and THYM as cancer lineages where C8orf82 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C8orf82 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C8orf82 survival associations across molecular data types. C8orf82 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C8orf82 RNA expression–survival associations across cancer types. High C8orf82 expression shows unfavorable associations in UVM, ACC and UCEC, but favorable associations in STAD, KIRC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for C8orf82 RNA expression.
This table summarizes C8orf82 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C8orf82. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C8orf82 shows lower tumor expression in KIRP and THCA and higher tumor expression in HNSC, LUSC, LUAD and STAD. The KIRP box plot shows higher C8orf82 RNA expression in normal versus tumor tissue (log2 FC = −0.608, t-test p < 0.001).
This table shows molecular features associated with C8orf82 in patient tissues and cancer cell lines. In patient samples, C8orf82 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C8orf82 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
